BMEABiomea Fusion, Inc.

Nasdaq biomeafusion.com


$ 10.45 $ -0.43 (-3.95 %)    

Thursday, 30-May-2024 15:59:54 EDT
QQQ $ 454.82 $ -4.89 (-1.07 %)
DIA $ 398.57 $ -3.10 (-0.81 %)
SPY $ 530.36 $ -3.49 (-0.66 %)
TLT $ 91.26 $ 0.86 (0.97 %)
GLD $ 225.37 $ 0.41 (0.19 %)
$ 10.46
$ 10.94
$ 10.26 x 100
$ 14.82 x 100
$ 10.16 - $ 11.10
$ 8.13 - $ 43.69
1,003,415
na
375.41M
$ 0.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 10-30-2023 09-30-2023 10-Q
4 07-31-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 03-28-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-01-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-27-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-maintains-outperform-on-biomea-fusion-lowers-price-target-to-60

Oppenheimer analyst Hartaj Singh maintains Biomea Fusion (NASDAQ:BMEA) with a Outperform and lowers the price target from $7...

 hc-wainwright--co-reiterates-buy-on-biomea-fusion-maintains-50-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $50 price t...

 jp-morgan-maintains-neutral-on-biomea-fusion-raises-price-target-to-15

JP Morgan analyst Eric Joseph maintains Biomea Fusion (NASDAQ:BMEA) with a Neutral and raises the price target from $14 to $15.

 biomea-fusion-q1-eps-109-misses-091-estimate

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.9...

 oppenheimer-maintains-outperform-on-biomea-fusion-maintains-70-price-target

Oppenheimer analyst Hartaj Singh maintains Biomea Fusion (NASDAQ:BMEA) with a Outperform and maintains $70 price target.

 jp-morgan-downgrades-biomea-fusion-to-neutral-lowers-price-target-to-14

JP Morgan analyst Gavin Scott downgrades Biomea Fusion (NASDAQ:BMEA) from Overweight to Neutral and lowers the price target ...

 hc-wainwright--co-reiterates-buy-on-biomea-fusion-maintains-50-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $50 price t...

 truist-securities-reiterates-buy-on-biomea-fusion-maintains-55-price-target

Truist Securities analyst Robyn Karnauskas reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $55 price target.

 biomea-fusion-q4-eps-098-misses-085-estimate

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.8...

 recap-biomea-fusion-q4-earnings
Recap: Biomea Fusion Q4 Earnings
04/01/2024 13:50:06

 biomea-fusion-highlights-initial-data-from-the-first-two-type-1-diabetes-patients-dosed-with-bmf-219

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim ...

 hc-wainwright--co-reiterates-buy-on-biomea-fusion-maintains-50-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $50 price t...

 biomea-fusion-presents-patient-cohorts-in-covalent-111-displaying-a-durable-placebo-adjusted-mean-reduction-of-up-to-14-in-hba1c-while-off-therapy-at-week-26-after-bmf-219s-28-day-treatment-cycle-supporting-improved-pancreatic-function

Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and d...

 truist-securities-initiates-coverage-on-biomea-fusion-with-buy-rating-announces-price-target-of-55

Truist Securities analyst Robyn Karnauskas initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces...

 why-humana-shares-are-trading-lower-by-over-11-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earning...

 alaska-air-posts-upbeat-earnings-joins-xerox-united-rentals-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: A...

 biomea-fusion-highlights-recent-updates-and-anticipated-2024-corporate-milestones-at-42nd-annual-jp-morgan-healthcare-conference

Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label porti...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION